Search

Crinetics Pharmaceuticals Inc

Closed

SectorHealthcare

83.59 0.17

Overview

Share price change

24h

Current

Min

83.48

Max

83.62

Key metrics

By Trading Economics

Income

-5M

-128M

Sales

6.8M

11M

EPS

-1.23

Profit margin

-1,191.029

Employees

594

EBITDA

-5M

-127M

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

-1.52% downside

Dividends

By Acuity

Next Earnings

4 Aug 2026

Market Stats

By TradingEconomics

Market Cap

82M

4.4B

Previous open

83.42

Previous close

83.59

News Sentiment

By Acuity

53%

47%

279 / 342 Healthcare

Crinetics Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

9 Jul 2026, 23:56 UTC

Social Media
News

NVIDIA Corp shares are lower in after-market trading amid concerns about its AI sector performance and intensifying competition from other chip manufacturers.

9 Jul 2026, 23:51 UTC

News
Social Media

Meta Platforms Inc. shares advanced in after-market trading following the launch of Muse Spark 1.1, an AI model aimed at enhancing software development capabilities.

9 Jul 2026, 23:51 UTC

Social Media
News

Netflix is exploring strategies to boost subscriber engagement amid declining viewer interest. Shares fell in after-hours trading following these developments.

9 Jul 2026, 23:46 UTC

News

The United States Oil Fund LP is trading lower in after-market hours, reflecting ongoing geopolitical tensions and a flat trajectory since Thursday's close.

9 Jul 2026, 23:36 UTC

News

Starbucks is developing AI tools to save $2 billion, including $400 million in software costs. Shares are higher in after-market trading.

9 Jul 2026, 23:16 UTC

News

Micron Technology expands U.S. investment to $250 billion by 2035, boosting capital expenditures by $50 billion. Shares rise in after-market trading.

9 Jul 2026, 23:06 UTC

Social Media
News

Tesla shares declined in after-market trading following a Hold rating from Citizens' Andrew Boone, who cited caution on the company's AI timeline.

9 Jul 2026, 20:07 UTC

News

BMO Capital initiated coverage on Align Technology with an Outperform rating and a price target of $209, contributing to positive sentiment despite leadership changes.

9 Jul 2026, 20:07 UTC

Correlated Moves
News

The iShares Core U.S. Aggregate Bond ETF is advancing today, supported by a decline in Treasury yields and positive labor market data.

9 Jul 2026, 20:07 UTC

ETF Constituents
Correlated Moves
News
Social Media

SPDR S&P 500 ETF Trust advances amid mixed market sentiment and geopolitical tensions. Initial jobless claims fell to 215,000, supporting positive momentum.

9 Jul 2026, 20:07 UTC

ETF Constituents
Correlated Moves
News
Social Media

The iShares Russell 2000 ETF is gaining amid geopolitical tensions and positive economic indicators, despite earlier fluctuations in the session.

9 Jul 2026, 20:07 UTC

Social Media
News
Correlated Moves
Macro Event

The iShares iBoxx $ Investment Grade Corporate Bond ETF and iShares TIPS Bond ETF are trading higher, supported by falling Treasury yields and improved jobless claims.

9 Jul 2026, 20:07 UTC

News
Social Media

Alphabet Inc. shares are lower amid concerns about its AI competitiveness, as a report suggests Meta may surpass Google in frontier AI capabilities.

9 Jul 2026, 20:07 UTC

Social Media
Correlated Moves
News

Western Digital shares rise as Micron plans $250 billion investment in U.S. memory production, boosting demand and pricing in the memory chip sector.

9 Jul 2026, 20:07 UTC

Correlated Moves
Social Media
Macro Event
News

Applied Materials shares advanced on analyst target increases amid strong demand outlook. The Nasdaq 100's rise also supported the stock's performance.

9 Jul 2026, 20:07 UTC

Social Media
News
Correlated Moves

Broadcom Inc gains as it joins Morningstar's "Cheap Stocks to Buy" list and announces a multiyear, $30 billion partnership with Apple for chip production.

9 Jul 2026, 20:07 UTC

Correlated Moves
Social Media
News

Citibank's CIO survey shows Microsoft leads AI funding, with 69% from new budgets. Shares are trading higher amid positive sentiment and ongoing challenges.

9 Jul 2026, 20:07 UTC

News
Correlated Moves

Ethereum sees $70 million in ETF inflows, the largest in 28 days. Despite negative social media sentiment, the asset is trading higher since Wednesday's close.

9 Jul 2026, 20:07 UTC

Correlated Moves
News

Bitcoin rises to $63,300 as President Trump's comments ease geopolitical tensions. The Federal Reserve's policy review may also support investor confidence in the cryptocurrency.

9 Jul 2026, 20:07 UTC

Correlated Moves
News

Bitcoin rises to $63,300 as President Trump's comments ease geopolitical tensions. The Federal Reserve's review of monetary policy may also boost investor confidence.

9 Jul 2026, 20:07 UTC

News
Correlated Moves

Ethereum sees significant inflows of $70 million from ETFs, marking the largest daily increase in 28 days, contributing to its higher trading position since Wednesday.

9 Jul 2026, 20:06 UTC

News

J B Hunt Transport Services is higher today after Goldman Sachs and Citigroup raised their price targets, reflecting positive assessments of the company's performance.

9 Jul 2026, 20:06 UTC

News

MercadoLibre shares are lower as Bronstein, Gewirtz & Grossman, LLC announces an investigation into potential claims related to the company's financial practices.

9 Jul 2026, 20:06 UTC

Social Media
News

Shares of Alphabet Inc. are lower amid concerns over its AI competitiveness, following a report suggesting Meta may surpass Google in frontier AI capabilities.

9 Jul 2026, 20:06 UTC

Event
News
Social Media
Correlated Moves

Intuit Inc. shares rise as the company goes ex-dividend for $1.20. Investor interest grows amid overall market strength and positive sentiment in technology stocks.

9 Jul 2026, 20:06 UTC

News
Correlated Moves

Geopolitical tensions following U.S. airstrikes on Iran have increased demand for safe-haven currencies, with CHF/HKD trading slightly higher during Thursday's session.

9 Jul 2026, 20:03 UTC

News
Social Media
Event
Macro Event

PepsiCo Inc's stock is lower following mixed second-quarter earnings, with revenue at $24.18 billion but adjusted EPS of $2.20 missing estimates.

9 Jul 2026, 20:02 UTC

News

Cisco Systems is trading higher as investors respond to its focus on smart building technology, including a partnership showing significant energy efficiency gains.

9 Jul 2026, 20:02 UTC

Social Media
ETF Constituents
News

Invesco QQQ Trust trades higher, recovering above $713.75, as SpaceX's Nasdaq-100 inclusion boosts interest. Strong performances from Meta, Broadcom, and AMD support the ETF.

9 Jul 2026, 20:02 UTC

Macro Event
News
Social Media
Correlated Moves

KLA shares advance as TD Cowen raises price target to $260. Positive sentiment in the semiconductor sector supports the upward movement amid increased AI demand.

Peer Comparison

Price change

Crinetics Pharmaceuticals Inc Forecast

Price Target

By TipRanks

-1.52% downside

12 Months Forecast

Average 82.22 USD  -1.52%

High 95 USD

Low 55 USD

Based on 14 Wall Street analysts offering 12 month price targets forCrinetics Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

14 ratings

3

Buy

11

Hold

0

Sell

Sentiment

By Acuity

279 / 342 Healthcare

News Sentiment

Bearish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
help-icon Live chat